Tag Archives: Hepatitis C

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Posted in Biotech, healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Also tagged , , , , , , , , | 1 Comment

Changing the Hepatitis C Treatment Landscape

The American Journal of Managed Care (AJMC) recently convened an expert panel that analyzed the implications of recommendations by the US Preventive Services Task Force that all Americans born between 1946 and 1964 be screened for the hepatitis C virus (HCV). Widespread screening, along with new therapies that move patients from a chronic condition to […]
Posted in Strategy | Also tagged , | 1 Comment

Woodcock Urges Forward March Toward Personalized Medicine

New approaches for conducting clinical trials and developing therapies that actually prevent and cure disease are key to the future of effective drug therapy, according to Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER). Personalized medicine has achieved mainstream status, accounting for more new drug approvals and promising pipeline candidates, […]
Posted in Technology | Also tagged , , , , , , , , , , | Leave a comment

Hepatitis C: Engaging Patients Online

Given the amount of activity in the hepatitis C drug development space – as evidenced in PharmExec’s 2013 Pipeline report – patients are scouring the internet for information on the disease, available treatments, and soon to be available treatments. A new Industry Standard Research report examines the digital cracks consumers encounter when looking for information […]
Posted in Advertising, E-Media, Marketing, multimedia, patient education, social media, Strategy | Also tagged , , , , , , | Leave a comment

Vertex Names Emmens President, Future CEO

Vertex Pharmaceuticals Thursday appointed Matthew Emmens president, with an expected transition to CEO and chairman in May 2009, when current CEO Joshua Boger is set to retire. Emmens, a 35-year pharma industry veteran, has been a Vertex director since 2004. He previously served as CEO of Shire plc and Astra Merck Inc., and as president […]
Posted in People | Also tagged , , , | Leave a comment
  • Categories

  • Meta